Global inflation trends, uneven central bank policies, and shifting energy costs are creating a market where headline noise can obscure quieter opportunities. While growth stories grab attention, many investors are looking for stocks where cash flows do more of the talking than market sentiment. The Undervalued Stocks Based On Cash Flows screener focuses on companies that SWS DCF valuation suggests are trading below fair value, with cash flow profiles that may support their fundamentals. In this article, you will see 3 of the most interesting stocks from this screener that could merit a closer look for a value-focused portfolio.

Broadcom (AVGO)

Overview: Broadcom is a large US$ digital infrastructure company that designs semiconductor chips and enterprise software used to move, store, secure, and manage data across data centers, AI systems, telecom networks, and connected devices.

Operations: Broadcom generates about US$27.7b from Infrastructure Software and roughly US$47.8b from Semiconductor Solutions and intellectual property licensing.

Market Cap: US$1.77t

Investors watching AI infrastructure, data centers, and cash flow rich businesses may find Broadcom interesting because it sits at key choke points of the digital economy while delivering net margins around 38.8% and returns on equity. The stock is currently indicated as trading about 10.3% below the Simply Wall St DCF fair value estimate. Analysts expect earnings and revenue growth above 20% per year. However, recent volatility around AI guidance shows sentiment can swing quickly. High debt levels and recent insider selling mean you need to weigh funding risk and governance quality against Broadcom’s cash generation, major AI partnerships, and large-scale custom silicon projects that many investors may still be underestimating.

Broadcom’s AI cash flows and 38.8% net margins are getting plenty of attention, but fewer investors are comparing that story with analyst forecasts. See how the analyst forecasts for Broadcom reshapes the risk reward picture.

Merck (MRK)

Overview: Merck is a global healthcare company that develops prescription medicines, vaccines, and treatments for cancer, infectious diseases, and chronic conditions, while also providing a broad range of animal health products for livestock and pets.

Operations: Merck generates about US$58.9b from human pharmaceuticals, US$6.6b from Animal Health, and US$0.4b from other revenues.

Market Cap: US$317.8b

Merck attracts attention because it combines a large, diversified drug portfolio with a rapidly expanding oncology and immunology pipeline, supported by acquisitions and partnerships that have tripled its late stage projects. Analysts expect earnings to grow faster than revenue as new products like WINREVAIR and CAPVAXIVE build on the KEYTRUDA franchise, even as exclusivity risks loom. At the same time, high debt, pressure on current profit margins after a sizeable one off loss, and questions over long term GARDASIL demand and pricing policies keep the risk side very real. For investors weighing a 2.63% dividend yield against a stock that screens as undervalued on cash flows, Merck’s next few product launches and regulatory decisions may be crucial to watch.

Merck’s oncology and vaccine pipeline is accelerating while that 2.63% dividend screens as undervalued on cash flows. However, the real story sits inside the 2 key rewards and 4 important warning signs

Mobileye Global (MBLY)

Overview: Mobileye Global develops camera and software based driver assist and self driving systems that help cars avoid collisions, stay in lane, and eventually operate as fully autonomous vehicles for consumers, fleets, and robotaxi services worldwide.

Operations: Mobileye Global generates about US$2.0b from its core Mobileye segment and US$38m from Other activities.

Market Cap: US$7.0b

Mobileye Global sits at the center of the shift from basic driver assistance to hands free and eventually driverless mobility, with design wins for its EyeQ chips and SuperVision systems feeding into a long pipeline of OEM programs and a planned robotaxi rollout from 2027. The stock currently trades well below Simply Wall St’s modeled cash flow value even though analysts expect strong earnings growth and a move to profitability within 3 years, which puts it firmly on a cash flow focused watchlist. The catch is that losses are still large, funding relies on external borrowing, and tariffs or weaker auto demand in key markets like China could reduce volumes. As a result, the potential upside comes with meaningful execution and macro risk attached.

Accelerating design wins and a stock that screens well below modeled cash flow value suggest Mobileye Global’s story is only half told. See how the analysis report for Mobileye Global reframes the upside once funding and execution are fully unpacked.

The three stocks covered here are only a starting sample. The full Undervalued Stocks Based On Cash Flows screen surfaces 132 more companies where cash flow potential and discounted valuations create similarly compelling stories, all in one place via the Undervalued Stocks Based On Cash Flows screener. Use Simply Wall St to identify, filter, and analyze the specific catalysts and narratives that matter to you so you can focus on the highest conviction opportunities across that wider list.

Take Control of Your Investment Journey

If Merck or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Others Do

Fresh stock ideas do not stay under the radar for long. While the crowd chases yesterday's breakout, use focused screeners to spot momentum shifts early and act now.

• Target cash rich compounders by scanning a curated group of companies with resilient balance sheets using the list of solid balance sheet and fundamentals (48 results).
• Ride income momentum by filtering for high yield companies in the 9 dividend fortresses before payout stories become widely recognized.
• Explore developments in automation by reviewing hand picked companies inside the 29 robotics and automation stocks while the trend is still taking shape.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.